Provided by Tiger Trade Technology Pte. Ltd.

TransAtlantic

0.2460
0.0000
Volume:- -
Turnover:- -
Market Cap:18.70M
PE:-0.46
High:0.2460
Open:0.2460
Low:0.2460
Close:0.2460
52wk High:0.8400
52wk Low:0.1200
Shares:76.00M
Float Shares:39.47M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5370
EPS(LYR):-0.0973
ROE:-90.35%
ROA:-7.65%
PB:-0.96
PE(LYR):-2.53

Loading ...

TAT announces Amazing Thailand Chinese New Year 2026 in Bangkok and Hat Yai marking 51 years of Thailand-China relations

prnewswire
·
Feb 05

TAT Technologies Is Maintained at Buy by Benchmark

Dow Jones
·
Feb 04

TAT stages Amazing MuayThai Festival 2026 to elevate sports tourism through Thai heritage

prnewswire
·
Feb 02

Vietnam's Tourism Grows, Thailand Worries About Losing Competitiveness

Tempo
·
Jan 25

TAT Technologies Wins $14 Million Three-Year Landing Gear MRO Deal with U.S. Airline

TIPRANKS
·
Jan 21

Truist Raises Price Target on TAT Technologies to $61 From $52, Keeps Buy Rating

MT Newswires Live
·
Jan 09

TAT Technologies price target raised to $61 from $52 at Truist

TIPRANKS
·
Jan 09

Tomorrowland announces its first-ever Thailand edition, launching as a full-scale festival in December 2026

prnewswire
·
Jan 06

TAT Technologies Coverage Assumed by Lake Street at Buy

Dow Jones
·
Dec 31, 2025

Thailand welcomes 2026 with countdown celebrations anchored by Phayao and Su-ngai Kolok

prnewswire
·
Dec 25, 2025

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

GlobeNewswire
·
Nov 24, 2025

TAT Technologies Initiated at Buy by Benchmark

Dow Jones
·
Nov 17, 2025

TAT Technologies initiated with a Buy at Benchmark

TIPRANKS
·
Nov 17, 2025

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

GlobeNewswire
·
Nov 17, 2025

TAT Technologies Is Maintained at Buy by Truist Securities

Dow Jones
·
Nov 15, 2025

TAT Technologies price target lowered to $52 from $56 at Truist

TIPRANKS
·
Nov 14, 2025

Truist Lowers Price Target on TAT Technologies to $52 From $56, Keeps Buy Rating

MT Newswires Live
·
Nov 14, 2025

Jiangxi Biological's IPO: Heavy Reliance on Single Product, "Second Curve" Far Off, and Clouded Historical Background with Large Dividends Before Listing

Deep News
·
Nov 14, 2025

TAT Technologies Reports Robust Q3 2025 Financial Growth

TIPRANKS
·
Nov 13, 2025

Press Release: TAT Technologies Reports Third Quarter 2025 Results

Dow Jones
·
Nov 13, 2025